The partnership follows a strategic collaboration between Twist and LakePharma, announced last week, that involves the same technology.
The firms will use AbCellera's antibody discovery platform, which combines a variety of technologies including next-generation sequencing and bioinformatics.
As part of the Human Vaccines Project, researchers sequenced samples from three adults and three infants to identify sets of shared and unique circulating B cell receptors.
The companies will use Berkeley Lights' technology to improve Pfizer's monoclonal antibody discovery and gene editing workflows.
The planned instrument will help provide spatial information on both protein and RNA in tumor samples and will be powered by nCounter technology.
The custom-made software will also allow Twist's biopharmaceutical customers to access a proprietary G-protein coupled receptor target library.
Researchers discuss the need for antibody standards at a meeting, NPR reports.
The group this week published a set of initial guidelines for antibody validation meant as recommendations in advance of a larger meeting later this month.
The partners will collaborate on point-of-care tests for validating the identity and activity of biologics and biosimilars.
The move marks a step in the effort to improve antibody quality as the life science community becomes increasingly aware of the problem of faulty reagents.
Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.
St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.
St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.
In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.